A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity

Sustainable global immunization campaigns against COVID-19 and other emerging infectious diseases require effective, broadly deployable vaccines. Here, we report a dissolvable microarray patch (MAP) SARS-CoV-2 vaccine that targets the immunoresponsive skin microenvironment, enabling efficacious need...

Full description

Saved in:
Bibliographic Details
Published in:iScience 2022-10, Vol.25 (10), p.105045, Article 105045
Main Authors: Balmert, Stephen C., Ghozloujeh, Zohreh Gholizadeh, Carey, Cara Donahue, Williams, Li’an H., Zhang, Jiying, Shahi, Preeti, Amer, Maher, Sumpter, Tina L., Erdos, Geza, Korkmaz, Emrullah, Falo, Louis D.
Format: Article
Language:English
Subjects:
Immunology
Medical biotechnology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sustainable global immunization campaigns against COVID-19 and other emerging infectious diseases require effective, broadly deployable vaccines. Here, we report a dissolvable microarray patch (MAP) SARS-CoV-2 vaccine that targets the immunoresponsive skin microenvironment, enabling efficacious needle-free immunization. Multicomponent MAPs delivering both SARS-CoV-2 S1 subunit antigen and the TLR3 agonist Poly(I:C) induce robust antibody and cellular immune responses systemically and in the respiratory mucosa. MAP vaccine-induced antibodies bind S1 and the SARS-CoV-2 receptor-binding domain, efficiently neutralize the virus, and persist at high levels for more than a year. The MAP platform reduces systemic toxicity of the delivered adjuvant and maintains vaccine stability without refrigeration. When applied to human skin, MAP vaccines activate skin-derived migratory antigen-presenting cells, supporting the feasibility of human translation. Ultimately, this shelf-stable MAP vaccine improves immunogenicity and safety compared to traditional intramuscular vaccines and offers an attractive alternative for global immunization efforts against a range of infectious pathogens. [Display omitted] •An immunogenic, safe, shelf-stable microarray patch (MAP) SARS-CoV-2 vaccine•Polyfunctional cellular immunity and long-lasting antibody responses•Robust respiratory tract immunity via skin vaccination•Translational immune correlates of MAP SARS-CoV-2 vaccine in human skin Immunology; Virology; Medical biotechnology
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2022.105045